Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Louis Buscail

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-4276-1003; OpenAlex author ID A5077103144. Sources: OpenAlex.

Their work

Papers
41 (first author 2, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
57
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 4 papers · 2014: none · 2015: 3 papers · 2016: 3 papers · 2017: 3 papers · 2018: 2 papers · 2019: 2 papers · 2020: 6 papers · 2021: none · 2022: 2 papers · 2023: 3 papers · 2024: 5 papers · 2025: 2 papers · 2026: 4 papers

Papers 41

  1. [Oncolytic viruses and pancreatic cancer: rethinking the approach to overcome therapeutic resistance]. First author DOI 10.1051/medsci/2026115↗
  2. Development and validation of an epidemiological risk score for early detection of pancreatic cancer in high-risk individuals within the IMAGene project. Co-author DOI 10.1093/ije/dyag064↗
  3. SG33, a Vaccine Strain of Myxoma Virus with Oncolytic Potential, Exploits Macropinocytosis and Clathrin-Mediated Endocytosis for Entry into Pancreatic Cancer C… Co-author DOI 10.1177/10430342261441043↗
  4. A genome-wide CRISPR-Cas9 screen identifies TGN46 as a host determinant for H-1PV susceptibility in pancreatic adenocarcinoma Co-author DOI 10.64898/2026.03.06.710102↗
  5. Is survival influenced by metastatic site in synchronous metastatic pancreatic adenocarcinoma (PDAC)? A prospective real-world BACAP study. Co-author DOI 10.1016/j.esmogo.2025.100144↗
  6. Risk Assessment Models for Predicting Venous Thromboembolism in Patients with Pancreatic Cancer. Co-author DOI 10.3390/cancers17040597↗
  7. Predictive genomic and transcriptomic analysis on endoscopic ultrasound-guided fine needle aspiration materials from primary pancreatic adenocarcinoma: a prosp… Co-author DOI 10.1016/j.ebiom.2024.105373↗
  8. Minute virus of mice shows oncolytic activity against pancreatic cancer cells exhibiting a mesenchymal phenotype. Co-author DOI 10.1016/j.omton.2024.200780↗
  9. Prognostic impact of circulating tumor DNA detection in portal and peripheral blood in resected pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1038/s41598-024-76903-y↗
  10. Cytidine deaminase-dependent mitochondrial biogenesis as a potential vulnerability in pancreatic cancer cells. Co-author DOI 10.1038/s42003-024-06760-y↗
  11. Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs. Co-author DOI 10.1158/0008-5472.can-22-3219↗
  12. Preclinical development of non-viral gene therapy for patients with advanced pancreatic cancer. Co-author DOI 10.1016/j.omtm.2023.03.005↗
  13. Pancreatic Cancer Cell and Gene Biotherapies: Past, Present, and Future. First author DOI 10.1089/hum.2022.210↗
  14. Pancreatic Cancer in Chronic Pancreatitis: Pathogenesis and Diagnostic Approach. Last author DOI 10.3390/cancers15030761↗
  15. Endoscopic ultrasound as a reliable tool for assessment of pancreatic adenocarcinoma treatment: Example of in situ gene therapy. Co-author DOI 10.1055/a-1799-7774↗
  16. Cytidine deaminase regulates mitochondrial biogenesis in pancreatic cancer cells Co-author DOI 10.1101/2022.12.15.520429↗
  17. Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2020.102858↗
  18. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Co-author DOI 10.1038/s41575-019-0245-4↗
  19. Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes. Co-author DOI 10.1053/j.gastro.2019.12.009↗
  20. Primary Thromboprophylaxis in Pancreatic Cancer Patients: Why Clinical Practice Guidelines Should Be Implemented. Co-author DOI 10.3390/cancers12030618↗
  21. A New Score to Predict the Resectability of Pancreatic Adenocarcinoma: The BACAP Score. Co-author DOI 10.3390/cancers12040783↗
  22. Primary Thromboprophylaxis in Ambulatory Pancreatic Cancer Patients Receiving Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Tria… Co-author DOI 10.3390/cancers12082028↗
  23. Expression and Role of MicroRNAs from the miR-200 Family in the Tumor Formation and Metastatic Propensity of Pancreatic Cancer. Co-author DOI 10.1016/j.omtn.2019.06.015↗
  24. Liquid Biopsy Approach for Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers11060852↗
  25. [Venous thromboembolism and pancreatic cancer]. Co-author DOI 10.1016/j.jdmv.2018.05.003↗
  26. A prospective clinical and biological database for pancreatic adenocarcinoma: the BACAP cohort. Co-author DOI 10.1186/s12885-018-4906-4↗
  27. Exosomes for targeting KRAS in the treatment of pancreatic cancer Co-author DOI 10.1038/nrgastro.2017.113↗
  28. Commentary: Pancreatic cancer: is the worst to come? Co-author DOI 10.1093/ije/dyx143↗
  29. Gene Therapy for Pancreatic Cancer: Specificity, Issues and Hopes. Last author DOI 10.3390/ijms18061231↗
  30. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities. Last author DOI 10.1016/j.ejca.2015.11.012↗
  31. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Last author DOI 10.1038/ctg.2016.18↗
  32. Initial Characterization of Integrase-Defective Lentiviral Vectors for Pancreatic Cancer Gene Therapy. Co-author DOI 10.1089/hum.2015.151↗
  33. First-in-man phase 1 clinical trial of gene therapy for advanced pancreatic cancer: safety, biodistribution, and preliminary clinical findings. Co-author DOI 10.1038/mt.2015.1↗
  34. Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with a KRAS mutation assay using allelic discrimination improves the diagnosis of pancreatic… Last author DOI 10.1097/mcg.0000000000000053↗
  35. Salivary MicroRNA in Pancreatic Cancer Patients. Co-author DOI 10.1371/journal.pone.0130996↗
  36. Targeting miR-21 for the therapy of pancreatic cancer. Co-author DOI 10.1038/mt.2013.35↗
  37. [Kras oncogene and pancreatic cancer: thirty years after]. Last author DOI 10.1051/medsci/20132911015↗
  38. KRAS Mutations and Their Correlation With Survival of Patients With Advanced Pancreatic Cancer Last author DOI 10.1097/mpa.0b013e31826b388b↗
  39. The rescue of miR-148a expression in pancreatic cancer: an inappropriate therapeutic tool. Co-author DOI 10.1371/journal.pone.0055513↗
  40. Gene expression signature of advanced pancreatic ductal adenocarcinoma using low density array on endoscopic ultrasound-guided fine needle aspiration samples. Last author DOI 10.1016/j.pan.2011.12.003↗
  41. Molecular endoscopic ultrasound for diagnosis of pancreatic cancer. Co-author DOI 10.3390/cancers3010872↗

Closest collaborators

The 25 strongest of 57 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Pierre Cordelier · 27 shared papers, 2011–2026 · strength 3.60
  2. Barbara Bournet · 22 shared papers, 2011–2026 · strength 2.24
  3. Nelson Dusetti · 7 shared papers, 2020–2026 · strength 1.38
  4. Naïma Hanoun · 10 shared papers, 2013–2026 · strength 1.34
  5. Cindy Canivet · 8 shared papers, 2018–2026 · strength 1.13
  6. Guillaume Labrousse · 3 shared papers, 2024–2026 · strength 0.70
  7. Stéphane Bertagnoli · 2 shared papers, 2026 · strength 0.66
  8. Jérôme Torrisani · 8 shared papers, 2011–2024 · strength 0.66
  9. Marion Gayral · 6 shared papers, 2013–2024 · strength 0.62
  10. Dominique Farge · 5 shared papers, 2018–2025 · strength 0.61
  11. Charlotte Maulat · 4 shared papers, 2019–2024 · strength 0.60
  12. Fabrice Muscari · 7 shared papers, 2012–2024 · strength 0.58
  13. Corinne Frère · 4 shared papers, 2018–2025 · strength 0.55
  14. Audrey Lumeau · 3 shared papers, 2022–2024 · strength 0.46
  15. Audrey Francès · 3 shared papers, 2022–2024 · strength 0.46
  16. Étienne Buscail · 2 shared papers, 2019–2023 · strength 0.32
  17. Bertrand Napoléon · 3 shared papers, 2018–2022 · strength 0.31
  18. Lorraine Quillien · 1 shared paper, 2023 · strength 0.31
  19. Nikolaos Kontopoulos · 1 shared paper, 2026 · strength 0.30
  20. Margaux Vienne · 1 shared paper, 2024 · strength 0.23
  21. Guillaume Le Cosquer · 1 shared paper, 2023 · strength 0.22
  22. Eric Assénat · 3 shared papers, 2016–2020 · strength 0.22
  23. Odile Barbey · 2 shared papers, 2015–2023 · strength 0.21
  24. Serena Oliveri · 1 shared paper, 2026 · strength 0.21
  25. Lorenzo Gervaso · 1 shared paper, 2026 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.